Loading...
Docoh

Bruce Fund

Filed: 23 Aug 21, 4:53pm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM N-PX

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED MANAGEMENT INVESTMENT COMPANY

 

Investment Company Act File number: 811-01528

 

Bruce Fund, Inc.

(Exact name of registrant as specified in charter)

_____________

20 North Wacker Drive, Suite 2414, Chicago, IL 60606

(Address of principal executive offices) (Zip code)

_____________

Robert B. Bruce

20 North Wacker Drive, Suite 2414

Chicago, Illinois 60606

(Name and address of agent for service)

 

Registrant's telephone number, including area code: 312-236-9160

 

Date of fiscal year end: June 30

 

Date of reporting period: 07/01/2020 - 06/30/2021

 

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (Secs. 239.24 and 274.5 of this chapter),to file reports with the Commission, not later than August 31 of each

year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b 1-4).The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

 

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget C'OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. Sec. 3507.

 

 

 

 

Bruce Fund, Inc.        
Annual Proxy Report       
Report Period: July 1, 2020 to June 30, 2021      
         
SecurityTickerCusipMeetingProposedDescriptionVoteFor, AgainstFor or Against
Name  Date(M) or (S)  or AbstainManagement
         
ChevronCVX1667641005/26/2021MDirectorsYFF
ChevronCVX1667641005/26/2021MAuditorsYFF
ChevronCVX1667641005/26/2021MExecutive CompensationYFF
ChevronCVX1667641005/26/2021SScope 3 emissionsYAF
ChevronCVX1667641005/26/2021SNet zero 2050YAF
ChevronCVX1667641005/26/2021SPublic benefitYAF
ChevronCVX1667641005/26/2021SLobbyingYFA
ChevronCVX1667641005/26/2021SIndependent ChairmanYAF
ChevronCVX1667641005/26/2021SSpecial meetingYAF
         
SupernusSUPN8684591086/15/2021MDirectorsYFF
SupernusSUPN8684591086/15/2021MAuditorsYFF
SupernusSUPN8684591086/15/2021MExecutive CompensationYFF
SupernusSUPN8684591086/15/2021MIncentive PlanYFF
         
AppleAPPL0378331002/23/2021MDirectorsYFF
AppleAPPL0378331002/23/2021MAccountingYFF
AppleAPPL0378331002/23/2021MExecutive CompensationYFF
AppleAPPL0378331002/23/2021Sproxy accessYAF
AppleAPPL0378331002/23/2021SExecutive Compensation improveYAF
         
NewmontNEM6516391064/28/2021MDirectorsYFF
NewmontNEM6516391064/28/2021MAccountingYFF
NewmontNEM6516391064/28/2021MExecutive CompensationYFF
      Y  
MannkindMNKD56400P7065/20/2021MDirectorsYFF
MannkindMNKD56400P7065/20/2021MAccountingYFF
MannkindMNKD56400P7065/20/2021MExecutive CompensationYFF
         
Fate TheraputicsFATE31189P1026/2/2021MDirectorsYFF
Fate TheraputicsFATE31189P1026/2/2021MAccountingYFF
Fate TheraputicsFATE31189P1026/2/2021MExecutive CompensationYFF
Fate TheraputicsFATE31189P1026/2/2021MNew sharesYFF
         
ParatekPRTK6993743026/10/2021MDirectorsYFF
ParatekPRTK6993743026/10/2021MAccountingYFF
ParatekPRTK6993743026/10/2021MExecutive CompensationYFF
         
Ashland GlobalASH0441861041/28/2021MDirectorsYFF
Ashland GlobalASH0441861041/28/2021MAccountingYFF
Ashland GlobalASH0441861041/28/2021MExecutive CompensationYFF
Ashland GlobalASH0441861041/28/2021MIncentive planYFF
         
MerckMRK58933Y1055/25/2021MDirectorsYFF
MerckMRK58933Y1055/25/2021MCompensation YFF
MerckMRK58933Y1055/25/2021MAccounting YFF
MerckMRK58933Y1055/25/2021SWritten consentYAF
MerckMRK58933Y1055/25/2021SCovid-19 accessYAF
         
ChiasmaCHMA16706W1026/10/2021MDirectorsYAA
ChiasmaCHMA16706W1026/10/2021MAccountingYFF
ChiasmaCHMA16706W1026/10/2021MExecutive CompensationYFF
ChiasmaCHMA16706W1026/10/2021MCompensation Vote FrequencyY1YrF
         
PfizerPFE7170811034/22/2021MDirectorsYFF
PfizerPFE7170811034/22/2021MAccountingYFF
PfizerPFE7170811034/22/2021MExecutive CompensationYFF
PfizerPFE7170811034/22/2021SCovid-19 accessYAF
PfizerPFE7170811034/22/2021SPolitical spendingYFA
PfizerPFE7170811034/22/2021SIndependent ChairYAF
         
NexteraNEE65339F1015/20/2021MDirectorsYFF
NexteraNEE65339F1015/20/2021MAuditorsYFF
NexteraNEE65339F1015/20/2021MCompensationYFF
NexteraNEE65339F1015/20/2021MLong term incentivesYFF
NexteraNEE65339F1015/20/2021SWritten ConsentYAF
         
AllstateALL0200021015/25/2021MDirectorsYFF
AllstateALL0200021015/25/2021MAuditorsYFF
AllstateALL0200021015/25/2021MCompensationYFF
AllstateALL0200021015/25/2021SProxy accessYAF
         
Paratek Pharm.PRTK6993743026/9/2021MDirectorsYFF
Paratek Pharm.PRTK6993743026/9/2021MAuditorsYFF
Paratek Pharm.PRTK6993743026/9/2021MNew sharesYFF
         
Bausch HealthBHC0717341074/27/2021MDirectorsYFF
Bausch HealthBHC0717341074/27/2021MCompensationYFF
Bausch HealthBHC0717341074/27/2021MAuditorsYFF
         
FlotekFTK3433891026/3/2021MDirectorsYFF
FlotekFTK3433891026/3/2021MLong term Incentive PlanYFF
FlotekFTK3433891026/3/2021MCompensationYFF
         
AmercoUHAL0235861008/20/2020MDirectorsYFF
AmercoUHAL0235861008/20/2020MCompensationYFF
AmercoUHAL0235861008/20/2020MCompensation Vote FrequencyY3 yrs.F
AmercoUHAL0235861008/20/2020MAccountingYFF
AmercoUHAL0235861008/20/2020SBoard ActionsYFF
         
AbbvieABBV00287Y1095/7/2021MDirectorsYFF
AbbvieABBV00287Y1095/7/2021MAuditorsYFF
AbbvieABBV00287Y1095/7/2021MSay on PayYFF
AbbvieABBV00287Y1095/7/2021MIncentive StockYFF
AbbvieABBV00287Y1095/7/2021MStock PurchaseYFF
AbbvieABBV00287Y1095/7/2021MSupermajority eliminationYFF
AbbvieABBV00287Y1095/7/2021SLobbyingYFA
AbbvieABBV00287Y1095/7/2021SIndependent ChairYAF
         
ProthenaPRTAG728001085/18/2021MDirectorsYFF
ProthenaPRTAG728001085/18/2021MAuditorsYFF
ProthenaPRTAG728001085/18/2021MCompensationYFF
ProthenaPRTAG728001085/18/2021MLong term Incentive PlanYFF
ProthenaPRTAG728001085/18/2021MDistributable reservesYFF
         
AbbottABT0028241004/23/2021MDirectorsYFF
AbbottABT0028241004/23/2021MSay on PayYFF
AbbottABT0028241004/23/2021MAccountingYFF
AbbottABT0028241004/23/2021SLobbying DisclosureYFA
AbbottABT0028241004/23/2021MSupermajority eliminationYFF
AbbottABT0028241004/23/2021SRacial JusticeYAF
AbbottABT0028241004/23/2021SIndependent ChairYAF
         
Sirius XM HoldingSIRI82968B1036/3/2021MDirectorsYFF
Sirius XM HoldingSIRI82968B1036/3/2021MAccountingYFF
         
Duke EnergyDUK26441C2045/6/2021MDirectorsYFF
Duke EnergyDUK26441C2045/6/2021MAuditorsYFF
Duke EnergyDUK26441C2045/6/2021MCompensationYFF
Duke EnergyDUK26441C2045/6/2021SPolitical contributionsYFA
Duke EnergyDUK26441C2045/6/2021SIndependent ChairYAF
Duke EnergyDUK26441C2045/6/2021MSupermajority eliminationYFF
         
AvistaAVA05379B1075/11/2021MDirectorsYFF
AvistaAVA05379B1075/11/2021MAuditorsYFF
AvistaAVA05379B1075/11/2021MCompensationYFF
         
Xtant MedicalXTNT98420P30810/27/2020MDirectorsYFF
Xtant MedicalXTNT98420P30810/27/2020MAuditorsYFF
Xtant MedicalXTNT98420P30810/27/2020MEquity IncentiveYFF
Xtant MedicalXTNT98420P30810/27/2020MCompensationYFF
         
XCEL EnergyXEL98389B1005/19/2021MDirectorsYFF
XCEL EnergyXEL98389B1005/19/2021MAuditorsYFF
XCEL EnergyXEL98389B1005/19/2021MCompensationYFF
XCEL EnergyXEL98389B1005/19/2021SClimateYAF
         
IGM BiosciencesIGMS4495851086/24/2021MDirectorsYFF
IGM BiosciencesIGMS4495851086/24/2021MAuditorsYFF
IGM BiosciencesIGMS4495851086/24/2021MAuthorized sharesYFF
         
General ElectricGE3696041035/4/2021MDirectorsYFF
General ElectricGE3696041035/4/2021MAuditorsYFF
General ElectricGE3696041035/4/2021MCompensationYFF
General ElectricGE3696041035/4/2021MReverse SplitYFF
General ElectricGE3696041035/4/2021SBoard candidatesYAF
General ElectricGE3696041035/4/2021SIndependent ChairYAF
General ElectricGE3696041035/4/2021SNet ZeroYFF
         
CMS EnergyCMS1258961005/7/2021MDirectorsYFF
CMS EnergyCMS1258961005/7/2021MAuditorsYFF
CMS EnergyCMS1258961005/7/2021MCompensationYFF
CMS EnergyCMS1258961005/7/2021SGreenwashing AuditYAF

 

 

SIGNATURES

 

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Bruce Fund, Inc.

 

By: /s/ Robert B. Bruce

Robert B. Bruce, President

Date: 8/12/2021